Long-term follow-up in superficial transitional cell carcinoma of the bladder: prognostic factors for time to first recurrence, recurrence rate, and survival. Final results of a randomized trial comparing doxorubicin hydrochloride, ethoglucid, and transurethral resection alone. EORTC Genitourinary Tract Cancer Cooperative Group.
Kurth
K
K
Dept. of Urology, University of Amsterdam, NL.
Schroeder
F H
FH
Debruyne
F
F
Senge
T
T
Pavone-Macaluso
M
M
de Pauw
M
M
ten Kate
F
F
Sylvester
R
R
D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000601:surgery*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000627:therapeutic use*; D004987:Ethers / Q000627:therapeutic use*; D005009:Ethoglucid / Q000627:therapeutic use*; D005060:Europe; D005500:Follow-Up Studies; D006801:Humans; D015337:Multicenter Studies as Topic; D011379:Prognosis; D011897:Random Allocation; D001743:Urinary Bladder / Q000601:surgery*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000601:surgery*
D004987:Ethers; D005009:Ethoglucid; D004317:Doxorubicin